Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05960786
Other study ID # OLith10702
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2, 2023
Est. completion date December 7, 2023

Study information

Verified date February 2024
Source Otolith Labs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vertigo. The main question[s] it aims to answer are: - Which device do participants respond better to (that is, find more relief)? - To what degree do participants find relief? Participants will be: - Enrolled up to 49 days; 14 days in Baseline Phase (no device) and 21 days in Treatment Phase (study device) for Study Arm 1 or 28 days in Treatment Phase (study device) for Study Arm 2 - Randomized and stratified into groups based on diagnosis to be assigned a study device - Asked to use the study device as instructed by the study coordinator - Asked to download a study app to submit daily diaries regarding their symptoms and use of device, and to participate in tele-health visits with study coordinators - Asked to provide their vertigo diagnosis from their physician - Compensated for their participation Researchers will compare the randomized groups to see which groups respond better to which device.


Description:

This study is decentralized clinical trial. This study uses technology and and virtual meetings to communicate with study participants and collect study data. This study seeks to enroll until 36 participants in the MoW arm have completed the study, and until 72 participants have completed the QoL arm. All study participants that meet all of the inclusion, none of the exclusion criteria, and sign informed consent will be enrolled in the study. Participants will complete a one day enrollment meeting and an approximately 14 day Baseline Phase. After the Baseline Phase participants will be placed in one of two groups Moderate or Worse (MoW) group or Quality of Life (QoL) group based on the data collected about their vertigo during the Baseline Phase. Participants will then be randomized within their assigned group (MoW or QoL) at a 2:1 ratio to an active arm or sham arm to begin the Treatment Phase of the study. Participants will be sent a study device to use when they have a vertigo episode. Participants that enroll in the study are expected to participate up to 49 days with virtual meetings at the approximate intervals: MoW Group: Day 21, Day 24, Day 31, and Day 42 QoL Group : Day 16, Day, 24, Day 36, and Day 49 Participants will be required to complete the DHI (Dizziness Handicap Index), VSS (Vertigo Symptom Scale), Global Impression of Symptoms, and Global Impression of Change questionnaires. Otolith Labs received Therapeutic Breakthrough Device designation by the FDA in May, 2021


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date December 7, 2023
Est. primary completion date December 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - To be eligible to participate in this study, an individual must meet all the following criteria: - Diagnosed as having vestibular vertigo that is caused by one or more of: - Benign paroxysmal positional vertigo (BPPV) - Migraine associated vertigo (MAV, aka vertiginous migraines) - Meniere's disease (aka idiopathic endolymphatic hydrops) - Uncompensated unilateral vestibulopathy (such as arising from vestibular neuritis and labyrinthitis) - Vertigo that has been present for at least 90 days - Score greater than 35, and less than 91, on the Dizziness Handicap Inventory (corresponding to moderate to severe vertigo) - Smartphone, computer or tablet and access to internet for online enrollment, check-in and wrap-up meetings - Willingness to install and use the JotForm ePRO app - Residing in the United States - Willingness to be paid via Venmo or PayPal. Exclusion Criteria: - Surgery to the base of the skull within the last 6 months or plans for surgery to the skull during enrollment period - Any skull or neck implants such as but not limited to a cochlear implant, vascular stents, bone conduction implant, or deep brain stimulation device - History of vitreous detachment (aka floaters) in the last 90 days - Superior canal dehiscence (aka third window) or otic capsule dehiscence - Hyperacusis (aka hypersensitivity to loud sounds) - Currently undergoing vestibular rehabilitation therapy or planning to start vestibular rehabilitation therapy during the study. (People who have completed vestibular rehabilitation therapy, but in whom vestibular vertigo persists, will be permitted to enroll) - History of cerebrovascular disorders - Posterior fossa tumors (brain tumors located in the caudal third of the skull) - Vestibular schwannoma (non-cancerous tumor located on the vestibulo-cochlear nerve) - Cerebellar degeneration (progressive worsening of neurons behind the brain stem) - Taking benzodiazepines (e.g., clonazepam, lorazepam, diazepam) for vestibular issues.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Otoband Experimental
Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
Otoband Sham
Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.

Locations

Country Name City State
United States Otolith Labs Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Otolith Labs MCRA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Effectiveness of Rating Scales Comparison of Verbal Rating Scale vs. Numerical Rating Scale as representation of participant response to device treatment. Through 21 days of treatment phase of "moderate of worse" arm of study
Primary Moderate or Worse Change in Vertigo Severity Change in participant response to "How severe is your vertigo right now?" during vertigo episodes, compared to responses in baseline phase Through 21 days of treatment phase of "moderate of worse" arm of study
Primary Quality of Life Change in Scores Change in participant's Vertigo Symptom Scale (VSS) score, compared to baseline VSS score Day 28 of treatment phase of "quality of life" arm of study
Secondary Device Effectiveness Percent change in mean severity of vertigo episodes as reported by the participant during the Treatment phase, compared to the Baseline phase. 30 minutes post vertigo episode during the treatment phase
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT02533739 - Vestibular Disorder and Visuo-spatial Functions N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Completed NCT00765635 - Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Phase 4
Not yet recruiting NCT04929444 - Training to Improve Vertigo Management in Primary Care N/A
Not yet recruiting NCT04055766 - A Diagnostic Test on DeepDoc-an AI-based Decision Support System
Completed NCT04458376 - Internet-based Self-help Program for Vestibular Rehabilitation in Chronic Dizziness N/A
Recruiting NCT06332326 - Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients N/A
Completed NCT02938221 - Telemedical Examination of a Three-Component Oculomotor Testing Battery N/A
Active, not recruiting NCT02655575 - Assessment and Treatment of Patients With Long-term Dizziness in Primary Care N/A
Completed NCT02457455 - Urgent Medical and Surgical Conditions During Flights N/A
Enrolling by invitation NCT01426932 - The Head Impulse Test in the Screening of Vestibular Function N/A
Completed NCT00000359 - Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Phase 2
Not yet recruiting NCT06010550 - Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo
Not yet recruiting NCT06017466 - Translation and Implementation of the Dutch VVAS Score in Clinical Practice N/A
Completed NCT04598113 - Effect of Cervical Traction on Balance in Cervical Radiculopathy Patients N/A
Completed NCT05157399 - Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness N/A
Completed NCT05897853 - Impact of Vertigoheel® on Patients Suffering From Bilateral Vestibulopathy and Functional Dizziness
Completed NCT05221892 - Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo Phase 4